Evaluation of sulfasalazine neurotoxicity and nephrotoxicity in rats

被引：0
作者：
Davinson Chuka Anyogu [1 ]
Arinzechukwu Stephen Ezema [1 ]
Kamsiyochukwu Vivian Onuora [1 ]
John Ikechukwu Ihedioha [1 ]
机构：
[1] Department of Veterinary Pathology, Faculty of Veterinary Medicine, University of Nigeria, Enugu State, Nsukka
来源：
Comparative Clinical Pathology | 2025年 / 34卷 / 3期
关键词：
Nephrotoxicity; Neurotoxicity; Oxidative stress biomarkers; Sulfasalazine; Sulfonamide toxicity;
D O I：
10.1007/s00580-025-03638-1
中图分类号：
学科分类号：
摘要：
Sulfasalazine (SSZ) is a sulfonamide antibacterial drug used in treating ulcerative colitis, rheumatoid arthritis, and chronic inflammatory bowel disease. Toxic effects were reported in humans and animals. This study aims to evaluate the effects of varied oral doses of sulfasalazine therapy on the brain and kidney in the rat model. Twenty male Wistar rats were randomly assigned into four groups (A–D) of five rats each. Groups A, B, and C rats received 150-, 300-, and 600-mg/kg body weight of sulfasalazine by oral gavage for 30 days. Group D rats were the controls, given water placebo. Blood samples were collected for hemato-biochemical analyses. The kidneys and brains were processed for histopathology. Sulfasalazine significantly (p < 0.05) increased serum creatinine and urea levels at 300 mg/kg and 600 mg/kg, and significantly (p < 0.05) decreased serum SOD and catalase activities at 600 mg/kg in the rats. It also caused sub-meningeal edema at 150 mg/kg and non-suppurative meningitis at 300 mg/kg and 600 mg/kg. Renal tubular necrosis was seen in all the sulfasalazine-treated rats. The results suggest that sulfasalazine is nephrotoxic and may cause non-suppurative meningitis in rats. © The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2025.
引用
收藏
页码：323 / 331
页数：8
相关论文
共 45 条
  • [21] Issam S., Sihem E.A., Feinene C., Et al., Sulfasalazine-induced aseptic meningitis with positive rechallenge: a case report and review of the literature, Therapie, 68, 6, pp. 423-426, (2017)
  • [22] Jobanputra P., Amarasena R., Maggs F., Et al., Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events, BMC Musculoskelet Disord, 9, 1, (2008)
  • [23] Kaufman D.W., Kelly J.P., Jurgelon J.M., Et al., Drugs in the aetiology of agranulocytosis and aplastic anaemia, Eur J Haematol Suppl, 60, pp. 23-30, (1996)
  • [24] Lamb E.J., Price C.P., Creatinine, urea and uric acid, Tietz Fundamentals of Clinical Chemistry, pp. 363-372, (2008)
  • [25] Lay J.D., Hong C.C., Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL, Cancer Res, 67, pp. 3878-3882, (2007)
  • [26] Liedorp M., Voskuyl A.E., Van Oosten B.W., Axonal neuropathy with prolonged sulphasalazine use, Clin Exp Rheumatol, 26, 4, pp. 671-672, (2008)
  • [27] Linares V., Alonso V., Domingo J.L., Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity, Expert Opin Drug Saf, 10, 2, pp. 253-263, (2011)
  • [28] Misra H.P., Fridovich I., The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase, J Biol Chem, 247, pp. 3170-3175, (1972)
  • [29] NTP toxicology and carcinogenesis studies of salicylazosulfapyridine (CAS No. 599–79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies), Natl Toxicol Program Tech Rep Ser, 457, pp. 1-327, (1997)
  • [30] Neila F., Raoudha S., Chaker B., Sulfasalazine induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor, Int J Clin Pharm, 37, pp. 563-565, (2015)
12345